SASikiru Ademola Aremu

Sikiru Ademola Aremu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sikiru Ademola Aremu has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Neurobiobanking in Africa: accelerating stroke care equity, curation and research - a functional approach

    by Patrick Ashinze, Babas Puamus Oki, Frederick Moody, Sikiru Ademola Aremu, Abdulgafar Yusuf, Toyeeb Olasunkanmi Nurudeen, Umoh Unyimeobong Jackson, Adeshina Abdulbasit Ahmed, Peace Ngozi Okoro

    Neurobiobanking—the systematic collection, processing, and storage of central nervous system (CNS) tissues and associated data—holds immense promise for elucidating the genetic, molecular, and environmental determinants of stroke. In Africa, where stroke incidence is rising, age of onset is younger, and outcomes are poorer than in high-income settings, region-specific neurobiologic repositories can drive equitable research and tailored interventions. Despite significant advances through precision healthcare initiatives like H3Africa and the National Health Laboratory Service (NHLS) National Biobank, most countries still grapple with funding shortfalls, infrastructure gaps, trained personnel inadequacy and schismic regulatory frameworks. This focused communication outlines the current visage of neurobiobanking in Africa, showcases its critical role in addressing the continent’s huge stroke burden, and proposes actionable strategies to establish inclusive, ethically governed, and sustainable neurobiobank networks.

  • Top Cited Papers
    Open Access

    Cardiac myxomas: a review of current treatment approaches and emerging molecular therapies

    by Patrick Ashinze, Suvam Banerjee, Emmanuel Egbunu, Wuraola Salawu, Abdullaah Idris-Agbabiaka, Eniola Obafemi, Tolulope Joseph Olajuwon, Bethrand Chukwu, Sikiru Ademola Aremu, Olafisoye-Oragbade Oluwatosin David, et al.

    Background: Cardiac myxomas are the most common primary cardiac tumors, predominantly located in the left atrium. These benign tumors can obstruct blood flow, cause embolization, or produce systemic symptoms like fever. Diagnostic tools such as echocardiography play a critical role in their identification, while surgical resection remains the primary curative treatment. Although recurrence is rare, it occurs more frequently in patients with genetic predispositions, such as the Carney complex. The risk of life-threatening complications such as embolism and sudden death necessitates prompt diagnosis and management. Despite the success of surgical treatment, recent advances have introduced minimally invasive techniques and novel molecular therapies, particularly for recurrent cases. Main body: The epidemiology of cardiac myxomas highlights their rarity, with an incidence of 0.5–1 per million individuals annually. They are classified based on location, morphology, and whether they are sporadic or syndromic. Histologically, they originate from multipotent mesenchymal cells and present as gelatinous or solid masses. The genetic implicants, especially in familial cases, involve certain gene mutations, disrupting signaling pathways and leading to tumorigenesis. Diagnosis primarily relies on imaging, with transthoracic echocardiography being the first-line modality. Surgical resection, typically via median sternotomy, remains the gold standard treatment with a low recurrence rate. However, emerging molecular therapies, including gene editing, epigenetic interventions, stem cell therapy, and immunotherapy, offer promising avenues for managing complex or recurrent cases even though they are mostly in conceptual and preclinical phases. These molecular approaches target specific genetic and signaling pathways involved in myxoma formation and recurrence, and though they remain in experimental stages, the advent of gene therapy in oncology makes them the next best choice to watch out for. Conclusions: While surgical resection remains curative in most cases, recurrence, particularly in familial syndromes, requires vigilant monitoring and innovative treatments. Emerging molecular therapies show potential in offering personalized treatment options, although they are still inchoate. Further research is needed to improve delivery systems and minimize the challenges associated with these therapies, paving the way for more effective management strategies.


  • Open Access

    Diabetic ketoalkalosis: the dark, torrid horse of diabetic emergencies

    by Patrick Ashinze, Nelson Mafua, Suvam Banerjee, Eniola Obafemi, Akande Eniola, Egbunu Emmanuel, Akogwu Ocholi Edache, Aremu Sikiru Ademola, Chukwu Bethrand Ozioma, Peace Ngozi Okoro

    Diabetic ketoalkalosis (DKALK) is a rare but significant variant of diabetic emergencies, characterized by metabolic alkalosis rather than the typical acidosis seen in diabetic ketoacidosis (DKA). Despite its clinical importance, DKALK often goes unrecognized due to limited literature on its presentation and biochemical variables. This work examines the pathophysiology, clinical presentation, diagnostic challenges, management strategies, and implications for clinical practice of DKALK, drawing insights from case studies and research gaps in the field. Notable case studies underscore the diagnostic challenges and emphasize the importance of tailored management strategies for DKALK. Risk assessment involves recognizing predisposing factors such as severe vomiting, alcohol abuse, or concomitant diuretic use. Timely recognition and intervention are essential to prevent potentially life-threatening complications associated with DKALK. Continued research efforts are warranted to refine diagnostic criteria, optimize therapeutic approaches, and enhance early recognition of DKALK, ultimately improving patient outcomes in this challenging clinical scenario.